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Introduction: After definitive treatment of esophageal cancer, 
patients are at high risk for recurrence. Consistent follow-up is 
important for detection and treatment of recurrence. The optimal 
surveillance regimen remains undefined. We investigated posttreat-
ment recurrence patterns and methods of detection in survivors of 
esophageal cancer.
Methods: We retrospectively studied a cohort of patients who had 
undergone surgical resection for esophageal cancer at our institution 
between 1996 and 2010. Routine computed tomography scan and 
upper endoscopy were performed for surveillance.
Results: In total, 1147 patients with resected esophageal adenocarci-
noma or squamous cell carcinoma were included (median follow-up, 
46 months). Of these, 723 patients (63%) had received neoadjuvant 
therapy before surgery. During follow-up, there were 595 deaths 
(52%) and 435 recurrences (38%) (distant [55%], locoregional 
[28%], or both [17%]). Half of recurrences were detected as a result of 
symptoms (n = 217), 45% by routine chest and abdominal computed 
tomography scan (n = 194), and 1% by surveillance upper endoscopy 
(n = 6). The recurrence rate decreased from 27 per 100 person-years 
in posttreatment year 1 to 4 per 100 person-years in year 6. In the first 
2 years, the rate of recurrence was higher among patients who had 
received neoadjuvant therapy (35 per 100 person-years) than among 
those who had not (14 per 100 person-years) (p < 0.001).
Conclusions: The incidence of recurrence is high after esophagec-
tomy for cancer. Surveillance endoscopy has limited value for detec-
tion of asymptomatic local recurrence. The yield from follow-up 
scans diminishes significantly after the sixth year; surveillance scans 
after that point are likely unnecessary.
Key Words: Esophageal cancer, Surveillance, Endoscopy.
(J Thorac Oncol. 2013;8: 1558–1562)
Esophageal cancer is the seventh leading cause of cancer death in men in the United States. Nearly 90% of patients 
with this malignancy will eventually die of the disease.1 Even 
after treatment with curative intent, recurrence often devel-
ops in patients. Regular follow-up after definitive treatment is 
believed to be an important component of cancer care, poten-
tially allowing for earlier detection and better management of 
recurrences. Scant evidence exists on the optimal follow-up 
regimen and its impact. As a result, guidelines differ on the 
method and interval of follow-up for posttreatment surveil-
lance.2,3 The use of computed tomography (CT) scan, positron 
emission tomography (PET)/CT scan, upper endoscopy, and 
serum carcinoembryonic antigen levels for surveillance have 
all been reported.4,5 Although endoscopic ultrasound has been 
shown to be more sensitive than endoscopy alone for detection 
of locoregional recurrences, it has not been widely used for 
surveillance of asymptomatic patients.6–8 The efficacy of each 
surveillance modality has not been systematically assessed in 
large cohorts. Likewise, although there is no consensus on the 
optimal frequency of follow-up, several series have demon-
strated that most recurrences occur in the first 2 years after 
completion of treatment.4,5 The purpose of this study was to 
evaluate (1) the incidence of esophageal cancer recurrence, 
over time, after treatment with curative intent; (2) the means 
of detection of recurrence; and (3) the outcomes after recur-
rence. The ultimate goal was to provide data to support a 
rational follow-up regimen for surveillance of patients after 
treatment of esophageal cancer with curative intent.
PATIENTS AND METHODS
We conducted a single-institution, retrospective cohort 
study in which we reviewed patients who had undergone 
esophagectomy for pathologic stage I to III esophageal ade-
nocarcinoma or squamous cell carcinoma at Memorial Sloan-
Kettering Cancer Center (MSKCC) between 1996 and 2010. 
Staging was performed using the 7th edition of the American 
Joint Committee on Cancer Cancer Staging Manual.9 We 
extracted baseline information from a prospectively main-
tained database, including demographic variables, pathologic 
details, preoperative staging and treatment details, and post-
operative disease status and vital status. Of note, at MSKCC, 
it is our practice to use preoperative chemoradiation therapy 
in patients with clinical evidence of locoregional advanced 
disease (clinical stages II and III). Details on recurrences 
were obtained from medical records from MSKCC and 
outside institutions, when available, and from documented 
patient communications. In some instances, questionnaires 
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regarding recurrences and long-term complications were 
mailed every 2 to 3 years to patients who were not receiving 
follow-up at MSKCC. Recurrence status was censored on the 
date of the last MSKCC clinic visit or outside communication. 
Vital status was confirmed using the Social Security Death 
Index. The study was approved by the MSKCC Institutional 
Review Board.
Definition of Recurrence
After surgery, patients received regular follow-up from 
their surgeon and/or medical oncologist. Clinic visits took 
place every 4 to 6 months for the first 2 years after surgery 
and then yearly thereafter. Each visit consisted of a medical 
history, physical examination, and chest and abdominal CT 
scan. In general, surveillance upper endoscopy was performed 
every 6 months for 2 years and then yearly thereafter by either 
the primary surgeon or a gastroenterologist. Once a recur-
rence was suspected, patients underwent further workup that 
included PET/CT scan, endoscopic ultrasound, upper endos-
copy, biopsy, or other modalities specific to the suspected site 
of recurrence. The date of detection of recurrence was defined 
as the date at which the initial abnormal surveillance study or 
symptomatic presentation led to further workup and diagno-
sis of recurrence. Diagnosis of recurrence was adjudicated by 
pathologic confirmation or by findings by other study modali-
ties that led to changes in treatment. Locoregional recurrence 
was defined as a recurrence isolated to the area of the anasto-
mosis (perianastomotic) or in lymph nodes in the mediasti-
num and upper abdomen (supraceliac). Distant recurrence was 
defined as any spread of disease beyond a locoregional recur-
rence. Most patients with confirmed recurrences received che-
motherapy; some received radiation therapy, when possible. 
Occasionally, patients received both. In patients who devel-
oped an isolated anastomotic recurrence and could tolerate 
further operation, surgical resection was performed.
Statistics
Summary statistics are presented as prevalence, mean 
± SD, and median. The average hazard rate of recurrence 
for each year after surgery was calculated at 12-month 
intervals, as number of recurrences per person-years of fol-
low-up during that interval. Time to recurrence and overall 
survival were estimated using the Kaplan–Meier method. 
Patients were followed up from the date of surgery until 
documented recurrence (for time to recurrence analysis) or 
death (for overall survival analysis). Patients who did not 
experience the corresponding event during the study period 
were censored at the time of the last available follow-up. In 
addition, in the group of patients who experienced recur-
rence, we estimated postrecurrence survival. The log-rank 
test was used for univariate comparison between groups. 
Multivariate analysis for postrecurrence survival was per-
formed using Cox proportional hazards regression, inves-
tigating the effect of recurrence type (locoregional versus 
distant, early versus late), controlling for age, disease stage, 
and neoadjuvant therapy use. The α value was set at 0.05. 
SAS version 9.3 (SAS Institute, Cary, NC) was used to per-
form all statistical analyses.
RESULTS
Of the 1373 patients who underwent esophagectomy at 
our institution between 1996 and 2010, 1147 were included 
in the study. Exclusion criteria were histologic type other 
than squamous cell carcinoma or adenocarcinoma (n = 36), 
Barrett’s esophagus or carcinoma in situ (n = 64), R2 resection 
(n = 95), stage IV disease (n = 25), primary resection not per-
formed at MSKCC (n = 4), and nonesophageal primary cancer 
(n = 2). Follow-up was performed through February 2012. The 
median follow-up for those alive and without recurrence at 
study end was 46 months (range, 0–192 months). Table 1 sum-
marizes patient and disease characteristics. Adenocarcinoma 
was the predominant histologic type (n = 942 [82%]). A 
total of 723 patients (63%) had received neoadjuvant therapy 
before surgery. Combined chemoradiation therapy was more 
common than chemotherapy alone. Only 7% of the patients 
(n = 77) had R1 resection. At the time of review, 435 patients 
(38%) had developed a recurrence and 595 patients (52%) 
had died (Figure 1). Of the 435 patients with evidence of 
recurrence, 241 (55%) had distant recurrence, 121 (28%) had 
locoregional recurrence, and 73 (17%) had both types.
TABLE 1.  Patient and Disease Characteristics (n = 1147)
Characteristic n (%)a
Sex
 Male 888 (77.4)
 Female 259 (22.6)
Age (yr)
 Mean (SD) 63 (10.7)
 Range 21–89
Histologic type
 Squamous cell carcinoma 205 (17.9)
 Adenocarcinoma 942 (82.1)
Induction therapy
 Chemotherapy 67 (5.8)
 Chemoradiation therapy 656 (57.2)
 None 424 (37.0)
Margins
 R0 1070 (93.3)
 R1 77 (6.7)
Pathologic stage
 0 154 (13.4)
 IA 194 (16.9)
 IB 172 (15.0)
 IIA 79 (6.9)
 IIB 264 (23.0)
 IIIA 140 (12.2)
 IIIB 71 (6.2)
 IIIC 73 (6.4)
Recurrence 435 (37.9)
 Distant 241 (55.4)
 Locoregional 121 (27.8)
 Distant + locoregional 73 (16.8)
aPercentage of all recurrences.
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Detection of Recurrence
For half of the patients (50%), suspicious symptoms 
(weight loss, dysphagia, shortness of breath, and neurologic 
symptoms) or abnormal physical examinations (cervical or 
supraclavicular adenopathy) ultimately led to the diagnosis 
of recurrence (Table 2). Surveillance chest and abdominal 
CT scans detected 45% of recurrences. Among asymptom-
atic patients, only six cases of recurrence (1%) were detected 
by surveillance upper endoscopy. Interestingly, the type of 
recurrence (distant versus locoregional) did not correlate with 
clinical or subclinical detection (50% versus 56% detected 
clinically in distant and locoregional recurrences, respec-
tively; p = 0.24). During 6 years of follow-up, the pattern of 
detection of recurrences remained unchanged (p = 0.85).
Upper Endoscopy Surveillance
Because upper endoscopy surveillance may have been 
performed and recorded less reliably at outside centers, we 
limited our examination of its efficacy to the periods of con-
tinuous follow-up at MSKCC. During follow-up at MSKCC 
(median, 31 months; range, 0–192 months), 367 recurrences 
were diagnosed, and only six (2%) were initially detected by 
surveillance upper endoscopy. More than half of the patients 
(n = 215 [59%]) with a documented recurrence underwent 
at least one endoscopy within 3 months (before or after) of 
the diagnosis of recurrence, either for screening or for further 
evaluation of possible recurrence; only 46 of these endoscopies 
(21%) detected any evidence of malignancy. Of the 40 patients 
who developed a perianastomotic recurrence, six patients 
(15%) had their recurrence initially detected by surveillance 
upper endoscopy, whereas most patients (n = 26 [65%]) pre-
sented with symptoms first (Table 3). Of the six patients whose 
perianastomotic recurrence was detected by upper endoscopy, 
one underwent a second resection with colon interposition, one 
received chemoradiation therapy, two underwent chemother-
apy alone, and two did not receive further treatment.
Time to Recurrence
In total, 75% of all recurrences occurred in the first 
2 years after surgery; this proportion was lower (63%) for 
patients who had not received neoadjuvant therapy than for 
those who had (83%) (p < 0.001). The median time to recur-
rence was 5.5 years (95% confidence interval [CI], 3.8–8.1 
years). The overall recurrence rate was 27 per 100 person-
years in postoperative year 1 (95% CI, 23–31 per 100 person-
years) and then rapidly decreased to 4 per 100 person-years 
by postoperative year 6 (95% CI, 2–8 per 100 person-years) 
(Figure 2). A similar pattern was observed when the analysis 
was limited to patients who had received neoadjuvant therapy. 
In this latter group of patients, however, recurrence occurred 
at a higher initial rate (35 per 100 person-years in postopera-
tive year 1; 95% CI, 30–40 per 100 person-years) (Figure 3). 
In contrast, patients who had not received neoadjuvant ther-
apy developed recurrences at a lower initial rate (14 per 100 
person-years; 95% CI, 10–19 per 100 person-years) but then 
experienced a slower rate of decline over time.
Survival
Supplementary Figure 1 (Supplementary Digital Content 
1, http://links.lww.com/JTO/A474) and Supplementary Figure 
2 (Supplementary Digital Content 2, http://links.lww.com/JTO/
A475) show overall survival following surgery among patients 
who had and had not received neoadjuvant therapy, strati-
fied by nodal stage and pathologic stage, respectively. Median 
FIGURE 1.  Time to recurrence in all patients.
TABLE 2.  Method of Detection in All Patients with a 
Recurrence (n = 435)
Method of Detection n (%)
Clinical (symptoms)a 217 (49.9)
Computed tomography 194 (44.6)
Upper endoscopy 6 (1.4)
Otherb 2 (0.5)
Unknown 16 (3.7)
aClinical detection includes symptoms and/or abnormal physical examinations.
bOther detection methods include tests not routinely performed at Memorial 
Sloan-Kettering Cancer Center: positron emission tomography/computed tomography, 
carcinoembryonic antigen level, chest radiograph, and magnetic resonance imaging.
TABLE 3.  Method of Detection and Upper Endoscopy in 
Patients with Perianastomotic Recurrence (n = 40)
Method of Detection/Upper 
Endoscopy
n (%)
Method of detection
 Clinical (symptoms) 26 (65.0)
 Computed tomography 5 (12.5)
 Upper endoscopy 6 (15.0)
 Unknown 2 (5.0)
 Chest radiograph 1 (2.5)
Upper endoscopy <3 mo after diagnosis of recurrence
 Yes 37 (92.5)
 No 3 (7.5)
Upper endoscopy findings (diagnostic or surveillance)
 Normal 5 (13.5)
 Abnormal 32 (86.5)
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postrecurrence survival among the 237 patients who experi-
enced recurrence was 11 months (Supplementary Figure 3, 
Supplementary Digital Content 3, http://links.lww.com/JTO/
A476). Patients whose recurrence was initially detected by radio-
graphic or laboratory tests had longer survival after diagnosis 
of recurrence than those who presented with symptoms and 
received clinical diagnosis (p = 0.01) (Supplementary Figure 
4, Supplementary Digital Content 4, http://links.lww.com/JTO/
A501). Likewise, the site of the first recurrence and the time to 
diagnosis of recurrence were associated with postrecurrence sur-
vival. Those with only locoregional disease (n = 121) (p < 0.001) 
and those whose recurrence was detected more than 2 years after 
surgery (n = 99) (p = 0.003) had longer survival, even after age, 
disease stage, and neoadjuvant therapy status were controlled for.
DISCUSSION
Esophageal cancer is an aggressive malignancy with high 
rates of recurrence, even after completion of therapy with cura-
tive intent. Current National Comprehensive Cancer Network 
guidelines2 recommend more-frequent follow-up, with medi-
cal history and physical examination, during the first 5 years. 
Surveillance modalities, such as CT scans, laboratory tests, and 
upper endoscopies, are recommended only as clinically indi-
cated. Many institutions (including ours), however, perform rou-
tine imaging and endoscopic examinations for surveillance of 
asymptomatic patients.2,4 The assumed value of a surveillance 
program is that the detection of recurrences at an earlier time 
might result in improved survival and quality of life. The ben-
efits of intensive surveillance, however, must be weighed against 
costs and potential side effects. At present, there is no consensus 
on the optimal follow-up regimen after esophagectomy for can-
cer. The aim of this study was to evaluate recurrence patterns 
after esophagectomy for cancer and, on the basis of these find-
ings, to propose a rational follow-up surveillance program.
Methods of Detection
Half of the patients (50%) who developed a recurrence 
initially presented with symptoms, even while undergoing 
routine surveillance imaging; 45% of patients who devel-
oped a recurrence were diagnosed by surveillance CT scan. 
This pattern of detection of recurrences remained the same 
throughout the follow-up period. Furthermore, recurrences 
detected clinically were associated with significantly worse 
survival, compared with recurrences detected subclinically, 
through surveillance screening. Because all patients under-
went a similar follow-up regimen and therefore had the same 
chance for early detection by surveillance, the association 
between method of diagnosis and survival is likely attribut-
able to a more aggressive tumor biology in patients diagnosed 
clinically, rather than to any benefit of “earlier” detection by 
surveillance screening. Nonetheless, our experience with rou-
tine CT scan points to its important role in the detection of 
recurrences before clinical presentation of symptoms. Our 
results differ from those of Abate et al.5 In their retrospective 
series on follow-up after treatment of esophageal adenocarci-
noma, only 17% of recurrences were diagnosed as a result of 
symptomatic presentation; 60% and 18% of recurrences were 
diagnosed by routine CT and PET scan, respectively. The dif-
ference in detection of recurrences between their study and 
ours may be attributable to several factors: the retrospective 
nature of both studies, the differences in follow-up protocols, 
and the definitions of “symptomatic recurrence” used. In con-
trast to the surveillance regimen in our study, their surveil-
lance regimen included more-frequent follow-up and routine 
PET/CT scans in some patients. Despite the differences in 
results, both series demonstrate that intensive follow-up with 
routine imaging effectively identifies subclinical recurrences.
Unlike CT scans, surveillance upper endoscopies rarely 
detected asymptomatic recurrences. Although there has been 
no published evidence on the efficacy of surveillance upper 
endoscopies, our follow-up regimen has included this modal-
ity because of its presumed ability to detect locoregional recur-
rences. Furthermore, perianastomotic disease recurrences are 
conceivably amenable to a second curative resection in select 
patients.10 Although upper endoscopy confirmed perianasto-
motic recurrence (when present) in the majority of patients 
(80%), the initiating event (i.e., symptom) that prompted the 
endoscopy was typically dysphagia (65%), rather than detec-
tion by any surveillance modality. In asymptomatic patients 
FIGURE 3.  Recurrence rates in patient with and without 
neoadjuvant therapy.
FIGURE 2.  Average hazard rate of recurrence in all patients.
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with perianastomotic recurrences, upper endoscopy rarely 
detected relapse (15%), which is likely attributable to the 
fact that this recurrence pattern often represents extraluminal 
nodal disease without endoluminal extension. Nevertheless, 
most patients with perianastomotic recurrences first presented 
with symptoms. Furthermore, only one of six patients whose 
recurrence was detected by surveillance endoscopy ultimately 
underwent further surgery with curative intent. Given the cost 
and invasiveness of this modality, surveillance upper endos-
copy seems to be of limited use for the follow-up of patients 
after curative treatment of esophageal cancer.
Timing of Recurrence
A rational follow-up regimen for surveillance of patients 
after esophagectomy for cancer should correspond to the like-
lihood of recurrence in the patients at risk (i.e., the recurrence 
rate), rather than the absolute number of patients experienc-
ing recurrence. Our current screening regimen includes more-
intense follow-up in the first 2 years—reflecting the belief 
that most recurrences occur during that period—followed by 
yearly CT scans thereafter, for an indefinite period. Indeed, we 
found that, overall, 54% and 21% of recurrences were diag-
nosed in the first and second years after surgery, respectively; 
these findings are similar to those described by Mariette et al.4 
The recurrence rate was highest in postoperative year 1 (27 
per 100 person-years). This rate then dropped quickly in year 2 
(17 per 100 person-years), after which it declined more slowly 
to 4 per 100 person-years by year 6. When the same analysis 
was performed on patients on the basis of whether they had 
received neoadjuvant therapy, we found that patients who had 
received neoadjuvant therapy had a very high initial rate of 
recurrence, followed by a sharp drop in the second year and 
a further drop in the third year; the rates then remained stable 
until year 5, before dropping thereafter. Among patients who 
had not received neoadjuvant therapy, the risk of recurrence 
was highest during the first year, followed by a stable risk of 
recurrence until year 4, with a decline in risk thereafter. This 
discordance in risk of recurrence over time likely reflects the 
initial stage of the disease. Neoadjuvant therapy was offered 
to patients with clinically advanced disease (clinical stages II 
and III) but not to those with an earlier clinical stage.
As the follow-up regimen should reflect the risk of 
recurrence, a more rational follow-up regimen for postinduc-
tion patients should therefore consist of short-interval follow-
up scans for 2 years, followed by yearly CT scans thereafter, 
whereas for noninduction patients, yearly CT scans should be 
sufficient. The ultimate duration of follow-up is debatable. 
However, after year 6, only 4% of patients at risk developed a 
recurrence (<2% of all recurrences), perhaps indicating a time 
point after which follow-up should be clinical only.
Recurrence Pattern
Previous studies have evaluated recurrence patterns in 
esophageal cancer.2,4,5 Similar to other investigators, we found 
that distant, locoregional, and mixed recurrences represented 
55%, 28%, and 17% of all new events, respectively. The site of 
the first recurrence was correlated with survival: patients with 
locoregional disease did the best, and patients with both distant 
and locoregional disease did the worst. This finding likely rep-
resents the overall tumor burden at the time of detection.
Limitations
Several limitations in our study should be noted. The 
details on recurrences were retrospectively obtained and 
are therefore subject to significant bias. As this is a single-
institution experience, our results may have limited general-
izability to other practices. Most importantly, this study was 
not designed to evaluate the effect of intensive follow-up on 
survival or patient-oriented outcomes. Although routine CT 
scans detected subclinical recurrences, prospective studies 
are needed to assess the effects of early diagnosis on survival, 
treatment outcomes, and quality of life.
CONCLUSION
Surveillance upper endoscopy rarely detected subclinical 
recurrences in survivors of esophageal cancer. Considering the 
costs and potential complications of the procedure, we do not rec-
ommend its routine use for follow-up of asymptomatic patients 
after surgical resection. CT scans of the chest and abdomen, on the 
other hand, were effective at identifying subclinical recurrences. 
For patients who have undergone preoperative treatment of clini-
cally advanced disease (clinical stage II or III), follow-up should 
be more frequent during the first 2 years (i.e., every 4–6 months), 
followed by yearly screening thereafter. For patients with earlier 
clinical stage disease, follow-up should be most frequent during 
the first year, followed by yearly CT scans afterward. As the yield 
from follow-up scans diminishes significantly after the sixth year, 
surveillance scans after that point are likely unnecessary.
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